These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23936497)

  • 21. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
    Noureddin M; Ghany MG
    Am J Gastroenterol; 2010 Oct; 105(10):2174-6. PubMed ID: 20927065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.
    Elgouhari HM; Zein CO; Hanouneh I; Feldstein AE; Zein NN
    Dig Dis Sci; 2009 Dec; 54(12):2699-705. PubMed ID: 19148751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection.
    Al-Ghamdi SMG; Alaulaqi N; Al-Amoudi AA; Alghamdi A; Zagnoon A; Sadiq BB
    Saudi J Kidney Dis Transpl; 2017; 28(4):799-805. PubMed ID: 28748882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
    Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment considerations in patients with hepatitis C and cirrhosis.
    Heathcote EJ
    J Clin Gastroenterol; 2003; 37(5):395-8. PubMed ID: 14564187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
    Di Bisceglie AM; Stoddard AM; Dienstag JL; Shiffman ML; Seeff LB; Bonkovsky HL; Morishima C; Wright EC; Snow KK; Lee WM; Fontana RJ; Morgan TR; Ghany MG;
    Hepatology; 2011 Apr; 53(4):1100-8. PubMed ID: 21480316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
    Gheorghe LS; Preda C; Iliescu L; Istratescu D; Chifulescu AE; Pop CS; Trifan A; Stanciu C; Diculescu M; Voiosu T; Baicus C; Tugui L; Iacob S; Tieranu C; Meianu C; Manuc M
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):385-390. PubMed ID: 32919421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
    Iacobellis A; Perri F; Valvano MR; Caruso N; Niro GA; Andriulli A
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):249-53. PubMed ID: 21092761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
    Di Bisceglie AM; Shiffman ML; Everson GT; Lindsay KL; Everhart JE; Wright EC; Lee WM; Lok AS; Bonkovsky HL; Morgan TR; Ghany MG; Morishima C; Snow KK; Dienstag JL;
    N Engl J Med; 2008 Dec; 359(23):2429-41. PubMed ID: 19052125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.